A - Agilent Technologies Short-Term Debt to Capital

Graphic logo of Agilent (A)

The history of the short interest ratio confirms the resilience of Agilent Technologies (A), which relies on a global installed base of instruments and high-margin services. The value of 0.01 serves as a baseline indicator of financial maturity amid expectations for a recovery in biotech demand, which the market currently prices in. Dominance in biopharma and the growth of cancer diagnostics ensure stability through recurring customer payments.

Short-Term Debt to Equity: Agilent Corp (A) for 07/04/2022 - 10/30/2026
Signature product of agilent.com

Agilent Technologies (A) is scaling the production of laboratory systems amid volatile demand from the biotech sector. This chart of the ratio between short-term liabilities and equity captures the share of obligations with maturities exceeding one year, determining the company's financial leverage. The current value of 0.01 allows for a real-time assessment of the business's dependence on borrowed capital under macroeconomic pressure from China. An increase in this indicator may enhance returns, but it raises the risk of asset drawdowns if client capital expenditures decline.

Main competitors

Short-Term Debt to Equity Quest (DGX)|Illumina Platform - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital EXAS (Exact Sciences)|Short-Term Debt to Capital revvity.com RVTY|BIO - Short-Term Debt to Equity|NNNN: Short-Term Debt to Equity|SHC (Sterigenics) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital QuidelOrtho Inc. (QDEL)|Short-Term Debt to Equity OPKO Health, Inc.|CareDx Corp (CDNA) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital MRVI|Short-Term Debt to Capital Coefficient Fulgent Genetics Inc|Short-Term Debt to Equity Fluidigm LAB|Short-Term Debt to Capital Coefficient Cytek Corp (CTKB)|OraSure Technologies - Short-Term Debt to Capital|XGN - Short-Term Debt to Capital|MDXH: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Lucid Diagnostics, Inc. LUCD|PRE (Prenetics Global Limited) - Short-Term Debt to Capital|Insight Molecular (IMDX) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Trinity Biotech plc (TRIB)|Short-Term Debt to Equity PRPH (prophaselabs.com)|Short-Term Debt to Capital AIMD (Ainos)|Co-Diagnostics Inc (CODX) - Current Liabilities to Capital|HSCS - Short-Term Debt to Equity|BMRA (Biomerica Inc) - Short-Term Debt to Capital Ratio|CDIO (cardiodiagnosticsinc.com) - Short-Term Debt to Equity Ratio|VRAX: Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio BJDX|AWH: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio AXDX (Accelerate Diagnostics, Inc)|Short-Term Loans to Capital Ratio CNTG|Short-Term Debt to Capital ENZ (Enzo Biochem)|Fresh2 Group Ltd (FRES) - Current Liabilities to Capital|GTG Labs - Short-Term Debt to Capital|23andMe Holding Co (ME) - Short-Term Debt to Equity Ratio|PMD: Short-Term Debt to Capital